Brief: NKMax And Merck Expand Clinical Collaboration
13/04/2021 14:33
April 13 (Reuters) - NKMAX CO LTD 182400.KQ :
* NKMAX AND MERCK KGAA, DARMSTADT, GERMANY EXPAND CLINICAL
COLLABORATION TO INCLUDE PHASE I/IIA TRIAL INVESTIGATING THE
COMBINATION OF SNK01 WITH ERBITUX® (CETUXIMAB) IN METASTATIC
NSCLC
Source text for Eikon: ID:nGNX3ZrhyM
Further company coverage: 182400.KQ
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 6600;))